INCY DMA

As of date:	3/30/2023
INCY stock price:	71.04
INCY 50 DMA:	77.91
INCY 200 DMA:	76.03
INCY MACD (200-50):	-1.88

Also see:
INCY Market Cap History
INCY Shares Outstanding History
INCY YTD Return
INCY RSI
INCY MACD
INCY Technical Analysis

Predict charts, win cash @ chartsweeps.com

CSQ Makes Bullish Cross Above Critical Moving Average
1 minute ago

PLUS Crosses Above Key Moving Average Level
1 minute ago

Pool Shares Cross Above 200 DMA
1 minute ago

Bullish Two Hundred Day Moving Average Cross - APOG
2 minutes ago

Bullish Two Hundred Day Moving Average Cross - UFPI
2 minutes ago

Bullish Two Hundred Day Moving Average Cross - MLAB
2 minutes ago

WEYS Crosses Above Key Moving Average Level
3 minutes ago

Bullish Two Hundred Day Moving Average Cross - SNOW
1 hour, 13 minutes ago

Postal Realty Trust (PSTL) Shares Cross Above 200 DMA
1 hour, 20 minutes ago

VSTO Makes Bullish Cross Above Critical Moving Average
1 hour, 23 minutes ago

VICI Properties Shares Cross Above 200 DMA
1 hour, 23 minutes ago

CTRE Crosses Above Key Moving Average Level
1 hour, 24 minutes ago

ATEN Crosses Above Key Moving Average Level
1 hour, 24 minutes ago

BST Crosses Above Key Moving Average Level
1 hour, 24 minutes ago

UE Crosses Above Key Moving Average Level
1 hour, 24 minutes ago

More Technical Analysis News

INCY DMA

INCY MACD

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) is Co.'s initial product approved by the U.S. Food and Drug Administration for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

When researching a stock like Incyte, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from INCY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for INCY stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the INCY 200 day moving average ("INCY 200 DMA"), while one of the most popular "shorter look-backs" is the INCY 50 day moving average ("INCY 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Incyte.

10 Most Oversold S&P 500 Stocks

10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying

10 ETFs With Most Upside To Targets

The DividendRank Top 25

Warren Buffett Dividend Stocks

10 Cheap Dividend Stocks Under $10

10 Top DividendRank'ed Energy Stocks

The 10 Highest Yielding Preferred Stocks

The 15 Most Active S&P Call & Put Options

Quotes delayed 20 minutes

Free INCY Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

Video: Technical Analysis

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Incyte (INCY) is categorized under the Healthcare sector; to help you further research DMA, below are some other companies in the same sector:

IQV DMA
ISRG DMA
JNJ DMA
LH DMA
LLY DMA
MCK DMA
MDT DMA
MMM DMA
MOH DMA
MRK DMA
More Healthcare companies »

INCY DMA | www.StockDMA.com | Copyright © 2019 - 2023, All Rights Reserved

Nothing in StockDMA.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.